Cambridge, UK
o2h Ventures is pleased to announce its recent seed eis investment in AscendBio, a company dedicated to pioneering synthetic biology solutions for combatting life threatening metabolic and respiratory diseases.
AscendBio is developing a revolutionary integrated cell programming platform to generate therapeutic cell types with unprecedented function and scalability for treating diseases. This innovative platform integrates design, engineering, and manufacturing processes, unlocking novel therapeutic possibilities and has been validated by producing therapeutic-grade liver cells with superior performance. They aim to fully exploit this integrated programming platform to develop multiple curative cell therapies across major therapeutic areas such as metabolic diseases, respiratory disorders, gastroenterology conditions as well as orphan indications.
Their Integrated Programming platform represents a significant leap in innovation, combining directed differentiation, forward programming, and tissue environment engineering to produce novel cell types tailored for therapeutic applications. The technology will also generate transformative organ-on-a-chip discovery platforms to revolutionize medicine development.
Sunil Shah, CEO of o2h Ventures, said:
Marcus has an amazing track record and a strong mix of both business and science, and we are very happy to support him on his entrepreneurial journey.
Dr Marcus Yeo, CEO of AscendBio, said:
We are delighted to receive preseed funding from a specialist Cambridge EIS technology fund and we look forward to developing a high-value company which can deliver curative therapies for patients.
About Ascend Bio
AscendBio’s mission is to transform the lives of patients with life-threatening metabolic and respiratory diseases. We have developed an optimized synthetic biology technology platform to generate new classes of highly functional curative cell therapy medicines by the Integrated Programming of stem cells.
About o2h Ventures
The o2h Ventures ‘Human Health’ SEIS and EIS funds make tax-efficient investments in Pre-Seed and seed-stage companies that address human disease: we fund the development of novel therapeutic treatments; we help build new services and tools offerings throughout the biotech ecosystem, and we spur the creation of software & artificial intelligence that will change healthcare.
The o2h team are leaders in the biotech community and have been actively involved as investors, holding various board/industry positions as well as being engaged in grassroots scientific activity for over 20 years. o2h Ventures operates from their proprietary 2.7 acre Mill SciTech Park where they are developing a unique model for incubating small life science companies.
For more information or to invest in the fund, please visit www.o2hventures.com
Media Contact:
Juhi Shah
Marketing Manager
